| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.006 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.007 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.007 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.009 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.096 | 0.009 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.009 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.01 |